The Bart Barlogie Clinical Investigator Award

In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Clinical Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.

The Bart Barlogie Clinical Investigator Award will be given to an investigator in recognition of their research in the myeloma field.

Maria-Victoria Mateos accepts the 2022 Bart Barlogie Award. Photo by ©IMS/Todd Buchanan 2022

Past Winner Profile

María-Victoria Mateos, MD, PhD is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit.

She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the setting of transplant ineligible and smouldering myeloma and these trials have profoundly influenced current options for the management of these patient populations.

She has published over 300 l-papers in international journals with a H index of 79 and 60 since 2015.

She is also a member of the IMS, IMWG, EHA and ASH.She has served on the ASH Scientific Committee on plasma cell diseases between  2015-2019 and on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2020 being chair of the Scientific Program Committee in 2019.

She has been Councillor on the EHA Board since 2015 for a four-year mandate and she remains as member of the IMS executive board and member of the European School of Haematology (ESH) Scientific committee. She received the Brian Durie Award in 2019 recognizing excellence in myeloma research.

Past Recipients

  • 2015 – B. Paiva
  • 2017– G. Palladini
  • 2019 – F. Gay
  • 2021 – S. Usmani

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events